<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00957060</url>
  </required_header>
  <id_info>
    <org_study_id>GLIME_L_04140</org_study_id>
    <nct_id>NCT00957060</nct_id>
  </id_info>
  <brief_title>Superiority of Glimepiride Over Sitagliptin in Naive Type 2 Diabetes Patients</brief_title>
  <acronym>SUMER</acronym>
  <official_title>A Multicenter, Open, Randomized, 24 Weeks Study to Evaluate the Superiority of Glimepiride Over Sitagliptin for the Treatment of naïve Patients With Type 2 Diabetes Mellitus</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sanofi</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sanofi</source>
  <brief_summary>
    <textblock>
      Primary Objective:

      To determine the superiority of glimepiride over sitagliptin in the reduction of HbA1c after
      6 months of treatment in patients with monotherapy until the end of the trial.

      Secondary Objective:

      To evaluate the effect of glimepiride compared to sitagliptin in:

      Glucose in fasting conditions; Postprandial glucose; Percentage of patients with HbA1c &lt; 7%
      and &lt; 6.5%; Symptomatic Hypoglycemia; Body weight; Percentage of withdrawal and percentage of
      patients with rescue therapy; Safety (adverse events and serious adverse events,
      hypoglycemia, vital signs and laboratory results).
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2009</start_date>
  <completion_date type="Actual">October 2010</completion_date>
  <primary_completion_date type="Actual">October 2010</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>HbA1c</measure>
    <time_frame>at baseline, week 12 and week 24</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Fasting and postprandial glucose</measure>
    <time_frame>at baseline, week 2, 4, 12 and 24</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">400</enrollment>
  <condition>Diabetes Mellitus, Type 2</condition>
  <arm_group>
    <arm_group_label>glimepiride</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The initial dose is 2 mg once a day. At week 2, the dose can be increased to 4 mg once a day according to the titration. At week 4 and 12, the dose can be increased from 2 mg to 4 mg or from 4 mg to 6 mg according to the titration.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>sitagliptin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>100 mg once a day. The dose will not be titrated.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GLIMEPIRIDE (HOE490)</intervention_name>
    <description>Pharmaceutical form: 2 mg and 4 mg tablets Route of administration: oral</description>
    <arm_group_label>glimepiride</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SITAGLIPTIN</intervention_name>
    <description>Pharmaceutical form: 100 mg tablets Route of administration: oral</description>
    <arm_group_label>sitagliptin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

          -  Subject naïve to treatment

          -  HbA1c &gt; 8.5 up to 11 %

          -  Lipid lowering therapy, antihypertensive, hormonal substitutes, thyroid hormone
             substitutes, and contraceptives are allowed as long as they are kept at a stable
             dosing

        Exclusion criteria:

          -  Treatment with any oral antidiabetics or insulin

          -  Known type 1 Diabetes Mellitus

          -  Pregnant or breast feeding women

          -  Ketoacidosis history

          -  History of sensitivity to any of the active substances

          -  Renal dysfunction : serum creatinine &gt; or = 1.5 mg/dL in male subjects &gt; or = 1.4
             mg/dL in female subjects

          -  Liver impairment (ALT, AST &gt; 3-fold the upper limit of normal range)

          -  Systemic corticosteroid treatment 3 months prior to study or during the study

          -  Drug or alcohol abuse history

          -  Patients with history of acute coronary syndrome, cerebrovascular events/transient
             ischaemic attack in the last three months

          -  Presence of any condition (medical, psychological, social or geographic) current or
             previously seen that according to Investigators judgment jeopardizes the safety or
             restricts the participation of the patient during the study

          -  Neoplasias

        The above information is not intended to contain all considerations relevant to a patient's
        potential participation in a clinical trial.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Judith Diaz</last_name>
    <role>Study Director</role>
    <affiliation>Sanofi</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Sanofi-Aventis Administrative Office</name>
      <address>
        <city>Guatemala City</city>
        <country>Guatemala</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis Administrative Office</name>
      <address>
        <city>Col. Coyoacan</city>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Guatemala</country>
    <country>Mexico</country>
  </location_countries>
  <verification_date>November 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 11, 2009</study_first_submitted>
  <study_first_submitted_qc>August 11, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 12, 2009</study_first_posted>
  <last_update_submitted>November 26, 2010</last_update_submitted>
  <last_update_submitted_qc>November 26, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 30, 2010</last_update_posted>
  <responsible_party>
    <name_title>Trial Transparency Team</name_title>
    <organization>sanofi-aventis</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glimepiride</mesh_term>
    <mesh_term>Sitagliptin Phosphate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

